Sartorius Stedim Biooutsource on Muck Rack

Sartorius Stedim Biooutsource

As seen in: Pharmaceutical Online, Bioprocess Online, Biosimilar Development
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sartorius Stedim

Contact Sartorius Stedim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Immuno-Oncology In Vitro Assays

|
By Ben Tyrrell, Katie Chapple, Sartorius Stedim Biooutsource
| Biosimilar Development
By Ben Tyrrell and Katie Chapple, Sartorius Stedim Biooutsource We offer a wide range of assay types and formats to characterize immune-oncology monoclonal antibodies (mAbs). In this application note, we discuss our recently developed assay format to characterize checkpoint inhibitor mAbs, specifically discussing those that target the PD-1 PD-L1 pathway.
Open in Who Shared Issue with article?

Immuno-Oncology In Vitro Assays

|
By Ben Tyrrell, Katie Chapple, Sartorius Stedim Biooutsource
| Pharmaceutical Online
By Ben Tyrrell and Katie Chapple, Sartorius Stedim Biooutsource We offer a wide range of assay types and formats to characterize immune-oncology monoclonal antibodies (mAbs). In this application note, we discuss our recently developed assay format to characterize checkpoint inhibitor mAbs, specifically discussing those that target the PD-1 PD-L1 pathway.
Open in Who Shared Issue with article?

Immuno-Oncology In Vitro Assays

|
By Ben Tyrrell, Katie Chapple, Sartorius Stedim Biooutsource
| Bioprocess Online
By Ben Tyrrell and Katie Chapple, Sartorius Stedim Biooutsource We offer a wide range of assay types and formats to characterize immune-oncology monoclonal antibodies (mAbs). In this application note, we discuss our recently developed assay format to characterize checkpoint inhibitor mAbs, specifically discussing those that target the PD-1 PD-L1 pathway.
Open in Who Shared Issue with article?
See all 3 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Sartorius Stedim

Contact Sartorius Stedim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified